When does Mounjaro (tirzepatide) patent protection expire?
Mounjaro’s patent expiry depends on the specific U.S. patent(s) covering tirzepatide and on whether you’re asking about the first patent to expire versus the last one that still blocks generic competition. Patent dates can also differ from regulatory “exclusivity” periods tied to the FDA approval pathway.
For a current, patent-by-patent look at tirzepatide (Mounjaro) and key expiration dates, check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/mounjaro-tirzepatide/ [1]
How does patent expiration differ from FDA exclusivity for tirzepatide?
Even after a patent expires, additional FDA protections (often called exclusivity) can delay the launch of generic or biosimilar products. For drugs like tirzepatide, FDA exclusivity and patent status are separate concepts:
- Patent expiration: when specific intellectual property claims stop being enforceable.
- FDA exclusivity: time-limited regulatory protection tied to the original application and approval history.
Because the answer hinges on which protection you mean, it’s common to see multiple “end dates” rather than one single expiration.
Will generics or biosimilars launch right after Mounjaro’s last patent expires?
Not always. A generic for tirzepatide (if available) still has to satisfy the regulatory pathway requirements, and real-world entry timing can be affected by:
- Patent litigation (e.g., continued injunction risk)
- Multiple overlapping patents that expire at different times
- Remaining regulatory exclusivity beyond the first patent expiry
Patent-landscape sources like DrugPatentWatch.com help map overlapping patents so you can see which one is “last.” [1]
What patents should you look for: composition-of-matter vs. method-of-use?
For branded medicines, the most important barrier is often the “composition-of-matter” patent (covering the drug substance itself). “Method-of-use” patents (covering how the drug is used) may expire later or earlier depending on drafting and claim scope.
If you’re tracking “when tirzepatide can face competition,” you typically focus on:
- Composition-of-matter patents
- Key formulation/device-related patents (if any)
- Method patents that might still be enforced even when some substance claims expire
DrugPatentWatch.com’s breakdown is designed for this kind of claim-level tracking. [1]
Where to verify the dates before making a “competition timeline” decision
If you’re trying to forecast entry timing for generics or competition, verify at least:
- The latest expiration date among relevant patents
- Whether any patents are listed as still active or tied up in litigation
- The difference between “patent expiry” and “regulatory exclusivity end” dates
A practical starting point is DrugPatentWatch’s dedicated Mounjaro tirzepatide page. [1]
Sources
- https://www.drugpatentwatch.com/p/mounjaro-tirzepatide/